References
- Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, people’s republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358.
- WHO Coronavirus (COVID-19) Dashboard. [ updated 2022 Jan 12] Available from: https://covid19.who.int/
- Beric-Stojsic B, Kalabalik-Hoganson J, Rizzolo D, et al. Childhood immunization and COVID-19: an early narrative review. Front Pub Health 2020;8:587007. https://doi.org/https://doi.org/10.3389/fpubh.2020.587007.
- Salman S, Salem ML. Routine childhood immunization may protect against COVID-19. Med Hypothes. 2020;140:109689.
- Gross R, Conzelmann C, Muller JA, et al. Detection of SARS-CoV-2 in human breastmilk. Lancet. 2020;395:1757–1758.
- Galang RR, Newton SM, Woodworth KR, et al. Risk factors for illness severity among pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection-surveillance for emerging threats to mothers and babies network, 22 state, local, and territorial health departments. Clin Infect Dis. 2021 March 29 2020-March 5 2021;73:S17–S23.
- Behera BC, Mishra RR, Thatoi HN. Recent biotechnological tools for diagnosis of coronavirus disease: a review. BiotechnolProg. 2021;37:e3078.
- Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Nat. 2020;583:459–468.
- Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–261.
- Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.
- Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nat. 2020;581(7809):465–469.
- Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatric Infect Dis J. 2005;24(11):S223–S227.
- Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. Clinic Med. 2020;21. 100331.
- Graham BS. Rapid COVID-19 vaccine development. Sci. 2020;368(6494):945–946.
- Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589.
- Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
- Shieber J Codagenix raises $20 million for a new flu vaccine and other therapies. tech crunch. [ updated 2021 Mar 27] Available from: https://techcrunch.com/2020/01/13/codagenix-raises-20-million-for-a-new-fluvaccine-andothertherapies/
- Zhang N, Li C, Hu Y, et al. Current development of COVID-19 diagnostics, vaccines and therapeutics. Microb Infect. 2020;22(6–7):231–235.
- McKay PF, Hu K, Blakney AK, et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun. 2020;11(1):1–7.
- Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11(12):836–848.
- Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261.
- Guallar-Garrido S, Julián E. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: an update. Immunotargets Ther. 2020;9:1–11.
- Alderton G. Repurposing existing vaccines. Sci. 2020;368(6496):1201–1203.
- Black S, Bloom DE, Kaslow DC et al. Transforming vaccine development . Seminar Immunol. 2020;50(101413): . https://doi.org/https://doi.org/10.1016/j.smim.2020.101413
- Oli AN, Obialor WO, Ifeanyichukwu MO, et al. Immunoinformatics and vaccine development: an overview. ImmunoTargetsTher. 2020;9:13.
- Chen HZ, Tang LL, Yu XL, et al. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. Infect Dis Poverty. 2020;9(1):1–10.
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations; 2021. Available from: https://www.who.int/news/item/07-05-2021-who-lists-additional-COVID-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
- Currier AW, Jeshurin MC, Sampson VB. SARS-CoV-2 targets and COVID-19 vaccines. COVID. 2021;1:608–621.
- Where, How Kazakhstan’s vaccine is developed [updated 2021 Apr 14] Available from: https://www.inform.kz/en/where-and-how-kazakhstan-s-homegrown-qazcovid-in-vaccine-is-developed_a3776423
- The Bharat Biotech BBV152 COVAXIN vaccine against COVID-19: what you need to know. World Health Organization [updated 2021 Nov 3] Available from: https://www.who.int/news-room/feature-stories/detail/the-bharat-biotech-bbv152-covaxin-vaccine-against-COVID-19-what-you-need-to-know
- A study to evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 vaccine (Vero cells), inactivated in healthy adults aged 18 years and older (COVID-19). US National Library of Medicine, Clinical trials.gov. updated 2021 Apr 22 Available from: https://clinicaltrials.gov/ct2/show/NCT04852705
- Study to compare the immunogenicity against COVID-19, of VLA2001 vaccine to AZD1222 vaccine (COV-COMPARE). US National Library of Medicine, Clinical trials.gov. [updated 2021 Oct 19] Available from: https://www.clinicaltrials.gov/ct2/show/NCT04864561
- Efficacy, Immunogenicity, and safety of the inactivated COVID-19 vaccine (TURKOVAC) versus the coronaVac vaccine. US National Library of Medicine, Clinical trials.gov. [updated 2021 Oct 19 Available from:https://clinicaltrials.gov/ct2/show/NCT04942405
- AboulFotouh K, Cui Z, Williams RO. Next-generation COVID-19 vaccines should take efficiency of distribution into consideration. AAPS PharmSciTech. 2021;22(3):126.
- Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2021;6736(21):02753–02757. https://doi.org/10.1016/S0140
- China’s CanSinoCovid Vaccine Shows 65.7% Efficacy. Bloomberg news [Rupdated 2021 Feb 8] Available form: https://www.bloomberg.com/news/articles/2021-02-08/pakistan-says-cansino-s-covid-vaccine-shows-65-7-efficacy
- A Phase III Clinical Trial of Influenza Virus Vector COVID- 19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1). WHO international clinical trials registry platform. Available form:[updated 2021 Sep 22] https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2100051391
- A heterologous prime-boost study to evaluate immunogenicity and safety of mRNA-1273 with MVC-COV1901 in adults. US National Library of Medicine, Clinical trials.gov. [updated 2021 Dec 10] Available from:https://clinicaltrials.gov/ct2/show/NCT05079633
- NovavaxCOVID-19 vaccine. Available from: https://en.wikipedia.org/wiki/Novavax_COVID-19_vaccine
- A phase III clinical trial to determine the safety and efficacy of ZF2001 for prevention of COVID-19. US National Library of Medicine, Clinical trials.gov. [updated 2021 May 7] Available from:https://clinicaltrials.gov/ct2/show/NCT04646590.
- Sanofi/GSK: recombinant protein. COVID-19 vaccine tracker. Available from: https://covid19.trackvaccines.org/vaccines/34/
- Soberana 02. Available from: https://en.wikipedia.org/wiki/Soberana_02#Efficacy
- EpiVacCorona. Available from: https://en.wikipedia.org/wiki/EpiVacCorona#Efficacy
- Abdala (vaccine). Available from: https://en.wikipedia.org/wiki/Abdala_(vaccine)#Efficacy
- A global phase III clinical trial of recombinant COVID- 19 vaccine (Sf9 cells). US National Library of Medicine, Clinical trials.gov. [updated 2021 May 27] Available from:https://clinicaltrials.gov/ct2/show/NCT04904471
- Nanocovax. Available from: https://en.wikipedia.org/wiki/Nanocovax#Efficacy_outcome
- Chavda VP, Vora LK, Vihol DR. COVAX-19Ⓡ vaccine: completely blocks virus transmission to non-immune individuals. Clinic Complement Med Pharmacol. 2021;1(1):100004.
- Immunogenicity and safety study of SK SARS-CoV-2 recombinant nanoparticle vaccine (GBP510) adjuvanted with AS03 (COVID-19). US National Library of Medicine, Clinical trials.gov. [updated 2021 Aug 17] Available from:https://clinicaltrials.gov/ct2/show/NCT05007951
- SCB–2019. Available from: https://en.wikipedia.org/wiki/SCB-2019#Efficacy
- Clinical Trials Registry India [Internet]. New Delhi: database publisher (India). 2021 August 31. Identifier CTRI/2021/08/036074, Biological E’s CORBEVAX vaccine clinical study for protection against Covid-19 disease; 2022 Jun 6 [cited 2022 Mar27]; Available from: https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-CTRI202108036074
- Comparison of the safety and efficacy of Fakhravac and Sinopharm SARS-CoV-2 vaccines, in adults aged 18 and over; a phase III randomized, non-inferiority clinical trial. Iranian registry of clinical trials. [updated 2021 Dec 20] Available from:https://en.irct.ir/trial/57980
- ZyCoV-D. Avaiable from: https://en.wikipedia.org/wiki/ZyCoV-D
- ISRCTN registry [internet]. London: BMC. [date unknown]- ISRCTN15779782, Solidarity trial of candidate vaccines against COVID-19; 2021 Oct 8 [Cited 2021 Oct 21]; Available from: https://www.isrctn.com/ISRCTN15779782
- Yan ZP, Yang M, Lai CL. COVID-19 vaccines: a review of the safety and efficacy of current clinical trials. Pharmaceutical. 2021;14:406.
- Chaudhary S, EI-Shorbagi AN, Gupta RK. Gupta RK, et al.the recent updates on approaches and clinical trials status of COVID-19 vaccines developed globally. Biomed Pharmacol J. 2021;14(3):1109–1124.
- Moderna’sCOVID-19 variant vaccines boost neutralizing titers in study. Pharmaceutical Technology [updated on 2021 April 16]. Available from: https://www.pharmaceutical-technology.com/news/moderna-COVID-19-variant-vaccines-study
- CureVacCOVID-19 vaccine. Available from: https://en.wikipedia.org/wiki/CureVac_COVID-19_vaccine
- A phase III clinical study of a SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine candidate against COVID-19 in population aged 18 years and above. US National Library of Medicine, Clinical trials.gov. [updated 2021 Nov 18] Available from:https://clinicaltrials.gov/ct2/show/NCT04847102
- India grants EUA to Bharat Biotech’s COVID-19 vaccine for use in children. Pharmaceutical technology [updated 2022 Jan 7].Available from: https://www.pharmaceutical-technology.com/news/india-bharat-biotech-children-covaxin/
- How effective is ZyCoV-D, the vaccine for adolescents? All about the needle-free, three-dose vaccine. Hindustan Times [updated 2022 Jan 10] Available from: https://www.hindustantimes.com/lifestyle/health/how-effective-is-zycov-d-the-vaccine-for-adolescents-all-you-want-to-know-101632390299445.html
- Pregnant Women Vaccinated Against COVID-19. (COVACPREG).US National Library of Medicine, clinical trials.gov. [updated 2021 Jul 12] Available from:https://clinicaltrials.gov/ct2/show/NCT04957953
- Sadat SM, Aghadadeghi MR, Yousefi M, et al. Bioinformatics analysis of SARS-CoV-2 to approach an effective vaccine candidate against COVID-19. MolBiotechnol. 2021;63:389–409.
- Min YQ, Mo Q, Wang J, et al. SARS-CoV-2 nsp1: bioinformatics, potential structural and functional features, and implications for drug/vaccine designs. Front Microbiol. 2020;11:2393.
- Poran A, Harjanto D, Malloy M, et al. Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. Genome Med. 2020;12(1):1–15.
- Murillo J, Villegas LM, Ulloa-Murillo LM, et al. Recent trends on omics and bioinformatics approaches to study SARS-CoV-2: a bibliometric analysis and mini-review. ComputBiol Med. 2020;128:104162 https://doi.org/https://doi.org/10.1016/j.compbiomed.2020.104162.
- Bhuiyan MU, Stiboy E, Hassan MZ, et al. Epidemiology of COVID-19 infection in young children under five years: a systematic review and meta-analysis. Vaccine. 2021;39(4):667–677.
- Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020;370:m3249.
- Public Health Agency of Canada (PHA). Canada COVID-19 weekly epidemiology report, June 13 to June 19 2021 (Week 24): Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases/2019novel-coronavirus-infection/surv-covid19-weekly-epi-update-20210625-en.pdf Accessed on Jul, 2021.
- Smith C, Odd D, Harwood R et al. Deaths in children and young people in England following SARS-CoV-2 infection during the first pandemicyear: anational study using linked mandatory child death reporting data. Nat Med. 2022;28;185–192 . https://doi.org/https://doi.org/10.1038/s41591-021-01578-1
- UNICEF data hub, COVID-19 and children. Available from: https://data.unicef.org/COVID-19-and-children.
- Molteni E, Sudre CH, Canas LS. Illness duration and symptom profile in a large cohort of symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health. 2021;5(10):708–718.
- Jain S, Sen S, Lakshmivenkateshiah S, et al. Multisystem inflammatory syndrome in children with COVID-19 in Mumbai, India. Ind paediatric. 2020;57(11):1015–1019.
- Balagurunathan M, Natarajan T, Karthikeyan J, et al. Clinical spectrum and short-term outcomes of multisystem inflammatory syndrome in children in a south Indian hospital. ClinExpPediatr. 2021;64(1):3.
- Flood J, Shingleton J, Bennett E, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): prospective, national surveillance, United Kingdom and Ireland, 2020. Lancet Reg Health Eur. 2021; 3: 100075.
- Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021 15; 385(3): 239–250.
- Product monograph (including patient medication information). Pfizer-BioNTechCOVID-19 vaccine: COVID-19 mRNA vaccine, suspension for intramuscular injection. [updated 2021 Nov 19] Available from: https://covid-vaccine.canada.ca/info/pdf/pfizer-biontech-COVID-19-vaccine-pm1-en.pdf.
- Snapiri O, Rosenberg Danziger C, Shirman N, et al. Transient cardiac injury in adolescents receiving the BNT162b2 mRNA COVID-19 vaccine. Pediatr Infect Dis J. 2021;40(10):e360–e363.
- Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in 7 adolescents after pfizer-BioNTechCOVID-19 vaccination. Pediatric. 2021;148(3):e2021052478.
- Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46.
- Lynch LR, Clifford H, Ko R, et al. Primer of COVID-19 vaccines for the perioperative physician. J NeurosurgAnesthesiol. 2022;34(1): 101–106.
- Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N Engl J Med. 2021;385(24):2241–2251.
- Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:1645–1653.
- Xia SL, Zhang YT, Wang YX, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2021;(21):00462–X. https://doi.org/10.1016/S1473-3099
- ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2021 Jun 09. Identifier NCT04918797, COVAXIN in a Pediatric Cohort (COVAXIN-Peds); 2021 July 2 [cited 2022 Mar 27]; Available from: https://www.clinicaltrials.gov/ct2/show/NCT0491879
- Clinical Trials Registry India [Internet]. New Delhi: database publisher (India). 2021 December 01-. Identifier CTRI/2021/01/030416, Novel Corona Virus-2019-nCov vaccine by intradermal route in healthy subjects; 2021 Dec 01[cited 2022 Mar27]; [3 page] Available from: https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/ictrp-CTRI202101030416
- CDC. COVID-19 response team, food and drug administration. Allergic reactions including anaphylaxis after receipt of the first dose of modernaCOVID-19 vaccine—United States. MMWR Morb Mortal Wkly Rep. 2021;70:125–129. December 21, 2020-January 10, 2021.
- Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225(3):303.e1–303.e17.
- Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med. 2021;384(24):2273–2282.
- Garg I, Shekhar R, Sheikh AB, et al. COVID-19 vaccine in pregnant and lactating women: a review of existing evidence and practice guidelines. Infect Dis Rep. 2021;13:685–699.
- Craig AM, Hughes BL, Swamy GK. Coronavirus disease 2019 vaccines in pregnancy. 2021;Am J ObstetGynecol MFM. 3:100295.
- Golan Y, Prahl M, Cassidy A, et al. COVID-19 mRNA vaccine is not detected in human milk. medRxiv. 2021. https://doi.org/10.1101/2021.03.05.21252998.
- Rottenstreich A, Zarbiv G, Oiknine-Djian E, et al. Efficient maternal fetal transplacental transfer of anti- SARS-CoV-2 spike antibodies after antenatal SARS-CoV-2 BNT162b2 mRNA vaccination. Clin Infect Dis. 2021;ciab266. https://doi.org/10.1093/cid/ciab266.
- Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine receptor system. Cytokine Growth Factor Rev. 2020;53:25–32.
- British Fertility Society and Association of Reproductive and Clinical Scientists (BFS & ARCS) COVID-19 vaccines & fertility. Available online: https://www.britishfertilitysociety.org.uk/2021/02/09/bfs-arcs-COVID-19-vaccines-fertility/ ( accessed on 2021 Jun 5).
- Orvieto R, Noach-Hirsh M, Segev-Zahav A, et al. Does mRNA SARS-CoV-2 vaccine influence patients’ performance during IVF-ET cycle? ReprodBiolEndocrinol. 2021;19:69.
- Jakuszko K, Ko´scielska-kasprzak K, Zabi ´nska M, et al. Immune response to vaccination against COVID-19 in breastfeeding health workers. Vaccines (Basel). 2021;9:663. https://doi.org/10.3390/vaccines9060663
- Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2–specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA. 2021;325(19):2013–2014.
- Dagan N, Barda N, Biron-Shental T, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 2021;27(10):1693–1695.
- Olliaro P, Torreele E, Vaillant M. Vaillant M.COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. Lancet Microbe. 2021;2(7):e279–e280.
- Bian L, Gao Q, Gao F, et al. Impact of the Delta variant on vaccine efficacy and response strategies. Expert Rev Vaccine. 2021;20:1201–1209.
- Pfizer–BioNTechCOVID-19 vaccine. Available from: https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine#cite_note-84
- Moderna_COVID–19_vaccine. Available from: https://en.wikipedia.org/wiki/Moderna_COVID-19_vaccine
- Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinic Microbiol Infect. 2021 https://doi.org/10.1016/j.cmi.2021.10.005
- Katella K Comparing the COVID-19 vaccines: how are they different?; 6th January, 2022. Available from:https://www.yalemedicine.org/news/COVID-19-vaccine-comparison
- Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891.
- Sheikh A, Mc Menamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–2462.
- Oxford–astraZeneca COVID-19 vaccine. Available from https://en.wikipedia.org/wiki/Oxford%E2%80%93AstraZeneca_COVID-19_vaccine
- Jones I, Roy P. Roy P.Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet. 2021;397(10275):642–643.
- Sputnik_V_COVID–19_vaccine. Available from:https://en.wikipedia.org/wiki/Sputnik_V_COVID-19_vaccine#Efficacy
- Ng OT, Koha V, Chiewd CJ, et al. Impact of Delta variant and vaccination on SARS-CoV-2 secondary attack rate among household close contacts. The Lancet Regional Health - Western Pacific. 2021; 17: 100299.